Involvement of cannabinoid receptors in gut motility and visceral perception.
From a historical perspective to the present day, all the evidence suggests that activation of cannabinoid receptors (CBRs) is beneficial for gut discomfort and pain, which are symptoms related to dysmotility and visceral perception. CBRs comprise G-protein coupled receptors that are predominantly in enteric and central neurones (CB1R) and immune cells (CB2R). In the last decade, evidence obtained from the use of selective agonists and inverse agonists/antagonists indicates that manipulation of CB1R can alter (1) sensory processing from the gut, (2) brain integration of brain-gut axis, (3) extrinsic control of the gut and (4) intrinsic control by the enteric nervous system. The extent to which activation of CB1R is most critical at these different levels is related to the region of the GI tract. The upper GI tract is strongly influenced by CB1R activation on central vagal pathways, whereas intestinal peristalsis can be modified by CB1R activation in the absence of extrinsic input. Actions at multiple levels make the CB1R a target for the treatment of functional bowel disorders, such as IBS. Since low-grade inflammation may act as a trigger for occurrence of IBS, CB2R modulation could be beneficial, but there is little supporting evidence for this yet. The challenge is to accomplish CBR activation while minimizing adverse effects and abuse liabilities. Potential therapeutic strategies involve increasing signaling by endocannabinoids (EC). The pathways involved in the biosynthesis, uptake and degradation of EC provide opportunities for modulation of CB1R and some recent evidence with inhibitors of EC uptake and metabolism suggest that these could be exploited for therapeutic gain.
Hornby
Pamela J
PJ
Enterology Research Team, Box 776, Johnson & Johnson Pharmaceutical Research and Development LLC, Welsh and McKean Roads, Spring House, PA 19477-0776, U.S.A. phornby@prdus.jnj.com
Prouty
Stephen M
SM
D000818:Animals; D063386:Cannabinoid Receptor Agonists; D063385:Cannabinoid Receptor Modulators / Q000494:pharmacology / Q000627:therapeutic use; D005769:Gastrointestinal Motility / Q000502:physiology*; D006801:Humans; D017288:Pain Threshold / Q000187:drug effects / Q000502:physiology*; D043882:Receptors, Cannabinoid / Q000502:physiology*; D017833:Visceral Afferents / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*
D063386:Cannabinoid Receptor Agonists; D063385:Cannabinoid Receptor Modulators; D043882:Receptors, Cannabinoid